Quarter-1 results for FY 2025-2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd reported its Q1 FY26 results for the quarter ended 30 June 2025. Consolidated revenue from operations rose to Rs 1,360.64 lakhs from Rs 1,169.29 lakhs in Q1 FY25, a growth of about 16% year-on-year, while standalone revenue jumped over 110% to Rs 1,338.35 lakhs from Rs 635.32 lakhs. Consolidated profit after tax more than quadrupled to Rs 11.77 lakhs (from Rs 2.73 lakhs), and standalone PAT surged to Rs 11.14 lakhs (from Rs 1.18 lakhs). Basic EPS stood at Rs 0.12 (consolidated) and Rs 0.11 (standalone). The auditor (Pundarikashyam and Associates) issued an unmodified review report with no qualifications or emphasis of matter, and the company confirmed no default on loans or debt securities.
Strong year-on-year rebound in both revenue and profitability, particularly on a standalone basis, signals improving business momentum and may be viewed positively by shareholders, though absolute earnings remain modest.